June M Chan1,2, Stacey A Kenfield1,2, Rebecca E Graff3,4, Crystal S Langlais1, Erin L Van Blarigan1,2, Claire H Pernar5, Meir J Stampfer5,6,7, Edward L Giovannucci5,6,7, Lorelei A Mucci5,7. 1. Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA. 2. Department of Urology, University of California, San Francisco, San Francisco, CA, USA. 3. Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA. Rebecca.Graff@ucsf.edu. 4. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA. Rebecca.Graff@ucsf.edu. 5. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA. 6. Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA. 7. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Abstract
BACKGROUND: Individual health behaviours have been associated with fatal prostate cancer (PCa). Their combined association with fatal PCa after diagnosis is unknown. METHODS: This prospective cohort included 4518 men diagnosed with nonmetastatic PCa from the Health Professionals Follow-up Study. Exposures included a three-factor score integrating post-diagnostic fatal PCa risk factors ("2021 PCa Behaviour Score"), six-factor score integrating incident aggressive PCa risk factors ("2015 PCa Behaviour Score"), and two scores integrating recommendations for cancer prevention and survival, respectively. Multivariable Cox models estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for fatal PCa. RESULTS: Over a median 10.2 years, we observed 219 PCa deaths. Each additional point of one of the PCa-specific health behaviour scores (2015 PCa Behaviour Score) was associated with a 19% reduced fatal PCa risk (HR: 0.81, 95%CI: 0.68-0.97). The 2021 PCa Behaviour Score and scores integrating national recommendations were not associated with fatal PCa. CONCLUSIONS: While a PCa-specific health behaviour score was associated with a reduced risk of fatal PCa, we did not otherwise observe strong evidence of associations between post-diagnostic scores and fatal PCa. Avoiding tobacco, healthy body size, and physical activity may decrease PCa death risk, but further research is needed to inform cancer survivorship recommendations.
BACKGROUND: Individual health behaviours have been associated with fatal prostate cancer (PCa). Their combined association with fatal PCa after diagnosis is unknown. METHODS: This prospective cohort included 4518 men diagnosed with nonmetastatic PCa from the Health Professionals Follow-up Study. Exposures included a three-factor score integrating post-diagnostic fatal PCa risk factors ("2021 PCa Behaviour Score"), six-factor score integrating incident aggressive PCa risk factors ("2015 PCa Behaviour Score"), and two scores integrating recommendations for cancer prevention and survival, respectively. Multivariable Cox models estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for fatal PCa. RESULTS: Over a median 10.2 years, we observed 219 PCa deaths. Each additional point of one of the PCa-specific health behaviour scores (2015 PCa Behaviour Score) was associated with a 19% reduced fatal PCa risk (HR: 0.81, 95%CI: 0.68-0.97). The 2021 PCa Behaviour Score and scores integrating national recommendations were not associated with fatal PCa. CONCLUSIONS: While a PCa-specific health behaviour score was associated with a reduced risk of fatal PCa, we did not otherwise observe strong evidence of associations between post-diagnostic scores and fatal PCa. Avoiding tobacco, healthy body size, and physical activity may decrease PCa death risk, but further research is needed to inform cancer survivorship recommendations.
Authors: Cheryl L Rock; Colleen Doyle; Wendy Demark-Wahnefried; Jeffrey Meyerhardt; Kerry S Courneya; Anna L Schwartz; Elisa V Bandera; Kathryn K Hamilton; Barbara Grant; Marji McCullough; Tim Byers; Ted Gansler Journal: CA Cancer J Clin Date: 2012-04-26 Impact factor: 508.702
Authors: S Chasan-Taber; E B Rimm; M J Stampfer; D Spiegelman; G A Colditz; E Giovannucci; A Ascherio; W C Willett Journal: Epidemiology Date: 1996-01 Impact factor: 4.822
Authors: Stacey A Kenfield; Julie L Batista; Jaquelyn L Jahn; Mary Kathryn Downer; Erin L Van Blarigan; Howard D Sesso; Edward L Giovannucci; Meir J Stampfer; June M Chan Journal: J Natl Cancer Inst Date: 2015-11-17 Impact factor: 13.506
Authors: Erin L Van Blarigan; Charles S Fuchs; Donna Niedzwiecki; Sui Zhang; Leonard B Saltz; Robert J Mayer; Rex B Mowat; Renaud Whittom; Alexander Hantel; Al Benson; Daniel Atienza; Michael Messino; Hedy Kindler; Alan Venook; Shuji Ogino; Edward L Giovannucci; Kimmie Ng; Jeffrey A Meyerhardt Journal: JAMA Oncol Date: 2018-06-01 Impact factor: 31.777
Authors: Crystal S Langlais; Rebecca E Graff; Erin L Van Blarigan; Nynikka R Palmer; Samuel L Washington; June M Chan; Stacey A Kenfield Journal: Curr Oncol Rep Date: 2021-03-10 Impact factor: 5.075